DE69942827D1 - Verwendung der epothilons zur behandlung der krebs - Google Patents

Verwendung der epothilons zur behandlung der krebs

Info

Publication number
DE69942827D1
DE69942827D1 DE69942827T DE69942827T DE69942827D1 DE 69942827 D1 DE69942827 D1 DE 69942827D1 DE 69942827 T DE69942827 T DE 69942827T DE 69942827 T DE69942827 T DE 69942827T DE 69942827 D1 DE69942827 D1 DE 69942827D1
Authority
DE
Germany
Prior art keywords
treatment
epothilone
epothilons
cancer
certain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942827T
Other languages
German (de)
English (en)
Inventor
Terence O'reilly
Markus Wartmann
Manuel Litchman
Pamela Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9803905.0A external-priority patent/GB9803905D0/en
Priority claimed from GBGB9803907.6A external-priority patent/GB9803907D0/en
Priority claimed from GBGB9805936.3A external-priority patent/GB9805936D0/en
Priority claimed from GBGB9805937.1A external-priority patent/GB9805937D0/en
Application filed by Novartis AG filed Critical Novartis AG
Priority claimed from PCT/EP1999/001147 external-priority patent/WO1999043320A1/en
Application granted granted Critical
Publication of DE69942827D1 publication Critical patent/DE69942827D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE69942827T 1998-02-25 1999-02-23 Verwendung der epothilons zur behandlung der krebs Expired - Lifetime DE69942827D1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9803905.0A GB9803905D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9803907.6A GB9803907D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9805936.3A GB9805936D0 (en) 1998-03-19 1998-03-19 Organic compounds
GBGB9805937.1A GB9805937D0 (en) 1998-03-19 1998-03-19 Organic compounds
US09/233,993 US6302838B1 (en) 1998-02-25 1999-01-19 Cancer treatment with epothilones
PCT/EP1999/001147 WO1999043320A1 (en) 1998-02-25 1999-02-23 Use of epothilones for the treatment of cancer

Publications (1)

Publication Number Publication Date
DE69942827D1 true DE69942827D1 (de) 2010-11-18

Family

ID=27451759

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69942827T Expired - Lifetime DE69942827D1 (de) 1998-02-25 1999-02-23 Verwendung der epothilons zur behandlung der krebs

Country Status (4)

Country Link
US (1) US6302838B1 (pt-PT)
JP (1) JP2011173928A (pt-PT)
AT (1) ATE483462T1 (pt-PT)
DE (1) DE69942827D1 (pt-PT)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
US20050042275A1 (en) * 1999-08-04 2005-02-24 Jean-Claude Sonntag Epothilone compositions
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US6489314B1 (en) * 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6893859B2 (en) * 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EE200300396A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
RU2313345C2 (ru) * 2001-02-27 2007-12-27 Новартис Аг Комбинации, содержащие ингибитор трансдукции сигнала и производное эпотилона
US7030147B2 (en) * 2001-03-19 2006-04-18 Novartis Ag Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US20070203346A1 (en) * 2001-04-30 2007-08-30 Oregon State University Method for synthesizing epothilones and epothilone analogs
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
CA2471509A1 (en) * 2002-01-14 2003-07-17 Novartis Ag Combinations comprising epothilones and anti-metabolites
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
MXPA04010853A (es) * 2002-05-01 2005-02-14 Novartis Ag Derivado de epotilona para el tratamiento de hepatoma y otras enfermedades de cancer.
WO2004103267A2 (en) * 2002-05-20 2004-12-02 Kosan Biosciences, Inc. Methods to administer epothilone d
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1506203B1 (en) 2002-08-23 2007-01-03 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
AU2003267751A1 (en) * 2002-10-15 2004-05-04 Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College Use of epothilone derivatives for the treatment of hyperparathyroidism
JP4939220B2 (ja) * 2003-05-15 2012-05-23 アークル インコーポレイテッド ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体
US20060205795A1 (en) * 2003-06-27 2006-09-14 David Parkinson Cancer treatment with epothilones
MXPA06002393A (es) * 2003-09-02 2006-06-20 Novartis Ag Tratamiento de cancer con epotilomas.
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7829560B2 (en) * 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
EP2258704A1 (en) * 2004-10-19 2010-12-08 ArQule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
WO2007131366A1 (en) 2006-05-16 2007-11-22 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2010065893A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. Raf inhibitors and their uses
BRPI1012246A2 (pt) * 2009-03-25 2016-03-29 Novartis Ag composição farmacêutica contendo um fármaco e sirna
AU2011214057B2 (en) 2010-02-12 2016-11-17 Pharmascience Inc. IAP BIR domain binding compounds
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
ES2178093T5 (es) 1995-11-17 2009-02-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Derivados de epotilon y su preparacion.
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
JP2001512723A (ja) 1997-08-09 2001-08-28 シエーリング アクチエンゲゼルシヤフト 新規エポチロン誘導体、その製法およびその薬学的使用

Also Published As

Publication number Publication date
US6302838B1 (en) 2001-10-16
ATE483462T1 (de) 2010-10-15
JP2011173928A (ja) 2011-09-08

Similar Documents

Publication Publication Date Title
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
CY1107637T1 (el) Θεραπευτικη αγωγη καρκινου προστατη με αντισωματα αντι - erbb2
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
NO20013444D0 (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
EA200101046A1 (ru) Производные индигоидных бис-индолов
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
MXPA03010909A (es) Derivados de epotilona.
BR0214787A (pt) Compósitos elastoméricos, combinações de elastÈmeros e métodos
PT1560812E (pt) Compostos de aminociclohexil eter e suas utilizacoes
HK1052940A1 (en) Synthetic methods for aplidine and new antitumoralderivatives, methods of making and using them
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
DE60030554T8 (de) Verwendungen von et743 zur behandlung von krebs
WO2003090680A3 (en) Novel phenyl derivatives as inducers of apoptosis
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
IS7562A (is) Sýanógúanidínforlyf
DE60226313D1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
ATE298328T1 (de) Taxan-derivate für die behandlung von krebs
ATE281455T1 (de) Oxindolderivate
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
DE60143023D1 (de) Tumorhemmende nitroacridin-zusammensetzungen
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
TR200003083T2 (tr) CNS hastalıklarının tedavisi için paroxetine 10-camphorsulfonate.

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN